Pharma: Page 2
-
AbbVie weathers first months of biosimilar challenge to top-selling Humira
While Humira sales declined, the drop was mostly due to price concessions AbbVie made to secure equal insurer access in the face of copycat competition.
By Ned Pagliarulo • April 28, 2023 -
Obesity drugs
Lilly plans dash to market for weight loss drug after trial win
The drugmaker will use a priority review voucher in a bid to secure FDA approval of Mounjaro in obesity by late this year or early next.
By Jonathan Gardner • April 27, 2023 -
Explore the Trendline➔
luismmolina via Getty ImagesTrendlineThe expanding world of RNA therapies
Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.
By BioPharma Dive staff -
Obesity drugs
Lilly drug Mounjaro succeeds in second weight loss study
Trial participants nearly 16% of their body weight in a finding that should help the closely watched GLP-1 drug gain an FDA approval for obesity.
By Jonathan Gardner • April 27, 2023 -
Bristol Myers’ Caforio stepping down as CEO in November
Commercial chief Christopher Boerner will take over after spending the next six months as chief operating officer. Giovanni Caforio will continue to serve as chair of Bristol Myers’ board.
By Jonathan Gardner • Updated April 26, 2023 -
Roche’s new eye drug pressures Eylea with strong launch
One year after its market debut, the company’s AMD drug Vabysmo is on track for blockbuster sales as Regeneron’s rival treatment faces new threats.
By Jonathan Gardner • April 26, 2023 -
Bristol Myers boosts cell therapy production with Novartis plant
Accessing the Illinois facility will expand Bristol Myers’ supply of viral vectors following manufacturing struggles with CAR-T drugs Abecma and Breyanzi.
By Kristin Jensen • April 26, 2023 -
Novartis trims 10% of drug pipeline in research cutback
The company cut about 20 early-stage projects, including nine solid tumor programs, after reviewing their strategic fit and commercial potential.
By Christopher Newman • April 25, 2023 -
J&J’s consumer health spinoff seeking $3B stock offering in test of IPO market
The planned IPO by the pharma’s consumer arm would value the new standalone company at over $40 billion.
By Ned Pagliarulo • April 25, 2023 -
Lilly sells emergency diabetes drug for $500M
The divestment of Baqsimi to Amphastar could net Lilly more than $1 billion if sales goals are met.
By Jonathan Gardner • April 24, 2023 -
Novartis plant cleared to produce in-demand cancer drug
The FDA has approved the pharma, which has had difficulty producing radiopharmaceutical drugs, to make its treatment Pluvicto at a New Jersey site.
By Delilah Alvarado • April 24, 2023 -
Ionis, AstraZeneca detail data backing rare disease rival to Alnylam drugs
A second-generation treatment called eplontersen halted nerve damage and improved quality of life in a late-stage study the companies are using to seek U.S. approval.
By Ned Pagliarulo • April 24, 2023 -
Sponsored by Qiagen
The rise of AI in pharma: make it work for you
AI-derived data can range from insightful to useless. Learn how to get one and not the other.
April 24, 2023 -
FatCamera |GettyImages-1456372164
Sponsored by ViatrisPartnership is key to caring for multiple sclerosis patients throughout their journey
Empowering people to live healthier goes beyond developing the right treatments.
By Anne Berger, Head of Alliance Development, Viatris • April 24, 2023 -
FDA approves earlier use of Roche’s Polivy in common form of lymphoma
The agency’s decision also converts the biologic drug's approval from accelerated to full, confirming an earlier OK based on tumor responses.
By Jonathan Gardner • April 20, 2023 -
Appeals court sides with Amgen in patent fight over psoriasis drug Otezla
With the court victory, the biotech giant could stave off a set of generic competitors for the top-selling drug until 2028.
By Kristin Jensen • April 20, 2023 -
J&J leans on cancer drug sales to maintain first quarter growth
Revenue topped analyst forecasts on strong market performance from the pharma’s multiple myeloma treatments, as well as the last quarter of significant COVID-19 vaccine sales.
By Christopher Newman • April 18, 2023 -
GSK to buy Bellus Health and its chronic cough drug for $2B
The acquisition gives GSK a competitor to a similar drug being developed by Merck for the condition, which the companies estimate affects millions of people in the U.S.
By Ned Pagliarulo • April 18, 2023 -
Vaxcyte strengthens case for experimental pneumococcal vaccine
The company reported positive results from a second Phase 2 study of a shot that’s meant to challenge vaccines from Pfizer, Merck and GSK.
By Delilah Alvarado • Updated May 3, 2023 -
Sponsored by Cardinal Health
Navigate the complexities of cell and gene therapies
See how the effective use of CMC expertise helped guide a biopharma company’s development of a CGT product.
April 17, 2023 -
FDA again knocks back Alvotech’s Humira biosimilar
The agency rejected the partners’ copycat version of AbbVie’s blockbuster drug for a second time, citing problems spotted during the inspection of a manufacturing facility.
By Jonathan Gardner • April 14, 2023 -
Novo boosts sales outlook on strong demand for obesity drug
The Danish drugmaker nearly doubled the 2023 forecasts for Wegovy and Ozempic in the latest indicator of the sales potential of an emerging and competitive class of weight loss drugs.
By Kristin Jensen • April 13, 2023 -
FDA, citing safety concerns, places partial hold on Merck KGaA’s MS drug
Evidence of possible liver damage among study participants adds to growing concerns about the potential of BTK inhibitors to treat MS, a strategy being pursued by several large drugmakers.
By Kristin Jensen • April 12, 2023 -
AbbVie removes two approvals for blood cancer drug Imbruvica
In paring back use of Imbruvica, the drugmaker has become the latest developer to voluntarily withdraw indications for a cancer medicine following a setback in confirmatory testing.
By Delilah Alvarado • April 7, 2023 -
National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.RSV vaccines
In NEJM, full Pfizer data show RSV vaccine’s protection
Shots from Pfizer and GSK could soon become the first approved for the common respiratory infection. Results published in the high-profile medical journal give a closer look at the former.
By Delilah Alvarado • Updated April 6, 2023 -
Pharma partner Sartorius eyes gene therapy market with $2.6B deal
The biotech tools supplier is acquiring Polyplus, a French company that makes components essential to the viral vector backbones of gene therapies.
By Ned Pagliarulo • March 31, 2023